[ad_1]
After being criticized last year for early deployment, the Russian Sputnik V vaccine is 91.6% effective against symptomatic Covid-19 and 100% effective against severe and moderate disease, according to an interim analysis of the results of the phase 3 trial of the vaccine.
The preliminary results were published in The Lancet on Tuesday and are based on data collected from 19,866 participants, of whom about three-quarters (14,964) received two doses of the vaccine and one-quarter (4,902) received a placebo.
Sixteen cases of symptomatic Covid-19 were confirmed in the vaccine group 21 days after participants received the first dose of vaccine. Sixty-two cases were found in the placebo group, ie an efficacy of 91.6%.
The trial included 2,144 people over the age of 60 and a sub-analysis of this group found that the vaccine was well tolerated and had a similar efficacy of 91.8%.
The team also analyzed the vaccine’s effectiveness against severe and moderate Covid-19 disease and 21 days after the first dose no severe or moderate cases were reported in the vaccinated group, while 20 were reported in the placebo group.
Serious adverse events were also rare and none were considered to be associated with vaccination. The majority of the side effects reported were mild, such as pain at the injection site, flu-like symptoms and low energy levels, according to the study.
The analysis only includes symptomatic cases of Covid-19, however, and the authors note that more research is needed to understand the effectiveness of the vaccine against asymptomatic Covid-19, transmission, and duration of protection.
The majority of trial participants were also white, so more research is needed to confirm the results in other ethics groups. The trial is also ongoing and aims to include a total of 40,000 participants.
Read the full story:
[ad_2]
Source link